Pulmonary Hypertension
COVID-19 leads to high in-hospital mortality for patients with pulmonary hypertension
In a cohort of patients with chronic precapillary pulmonary hypertension, the rates of in-hospital mortality for those who contracted COVID-19 were more than 40%, according to a study.
Adjusting for esophageal pressure in obesity may lower pulmonary hypertension risk
Adjusting pulmonary hemodynamics for esophageal pressure in patients with obesity and high pulmonary artery wedge pressure reduced the risk for postcapillary pulmonary hypertension diagnosis, according to findings published in Chest.
PAH management emphasizing right heart function in pregnancy led to better clinical outcomes
Multidisciplinary and tailored management of pulmonary arterial hypertension in pregnancy that emphasizes optimized right heart function before birth may lead to better clinical outcomes in a referral pulmonary hypertension center.
Selexipag improves pulmonary vascular resistance, other hemodynamics in CTEPH
Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic thromboembolic pulmonary hypertension, according to results published in European Respiratory Journal.
Women with PAH have ‘unique challenges’ around sexual health-related quality of life
A new study highlights significant burdens and challenges regarding sexual health-related quality of life for women with pulmonary arterial hypertension.
Noninvasive clinical tools predict severe pulmonary hypertension in COPD
The combination of echocardiography, N-terminal pro-B-type natriuretic peptide and pulmonary artery to ascending aorta diameter ratio predicted severe pulmonary hypertension in patients with COPD with high sensitivity and specificity.
FDA approves nitric oxide generator to treat neonates with hypoxic respiratory failure
Beyond Air has received FDA approval for nitric oxide generator and delivery system to treat term and near-term neonates with hypoxic respiratory failure
VIDEO: Updates in pulmonary hypertension highlighted at ATS 2022
SAN FRANCISCO — In this video exclusive, Belinda Natalia Rivera-Lebron, MD, MS, highlights recent updates in the treatment of pulmonary hypertension.
FDA approves inhaled treprostinil for treatment of PAH, pulmonary hypertension-ILD
United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
Combining endpoints may improve prediction of pulmonary hypertension survival
In a new study, improvements in multicomponent endpoints and risk stratification tools based on functional class, 6-minute walk distance and N-terminal pro-B-type natriuretic peptide better predicted pulmonary artery hypertension survival.